|Articles|October 1, 2012

The new drugs leading to substance abuse

Synthetic cannabinoids and cathinones have become drugs of abuse for adolescents and young adults. Research suggests that there is potential for great harm with chronic use.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

Repeal of nonmedical exemptions linked to rise in kindergarten vaccination rates

ByMorgan Ebert, Managing Editor

December 6th 2025

Hepatitis B Foundation president discusses recommendations for infant vaccination

ByChari A. Cohen, DrPH, MPH

December 5th 2025

ACIP votes to update hepatitis B vaccine recommendation for infants

ByJoshua Fitch, Senior Editor ,Morgan Ebert, Managing Editor

December 5th 2025

Christine Eng, MD, on addressing barriers to exome and genome sequencing in clinical practice

ByChristine Eng, MD

December 5th 2025

ACIP to vote on hepatitis B vaccination schedule as part of 2-day December meeting | Image Credit: © JHVEPhoto - © JHVEPhoto - stock.adobe.com.

ACIP delays vote on hepatitis B virus vaccine to December 5

ByJoshua Fitch, Senior Editor

December 4th 2025

Latest CME

Multimedia

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

In-Person + Virtual Event

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

January 23, 2026

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

The new drugs leading to substance abuse

Newsletter

Related Content

Repeal of nonmedical exemptions linked to rise in kindergarten vaccination rates

Hepatitis B Foundation president discusses recommendations for infant vaccination

ACIP votes to update hepatitis B vaccine recommendation for infants

Christine Eng, MD, on addressing barriers to exome and genome sequencing in clinical practice

ACIP delays vote on hepatitis B virus vaccine to December 5

Latest CME

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

ACIP votes to update hepatitis B vaccine recommendation for infants

New analysis highlights nirsevimab as most impactful RSV prevention strategy for infants

Hepatitis B Foundation president discusses recommendations for infant vaccination

Repeal of nonmedical exemptions linked to rise in kindergarten vaccination rates

FDA expands indication for MED-EL cochlear implants to infants 7 months or older